The parents of a 31-year-old woman have filed a wrongful death Toradol Stevens Johnson lawsuit against Pfizer, Inc. and Hospira Inc. after their daughter developed a fatal reaction to an anti-inflammatory drug.

Plaintiff Linda S. and Larry S. filed this Toradol Stevens Johnson lawsuit on behalf of their daughter Latrisha S. and her minor child after Latrisha suffered from Stevens Johnson syndrome and toxic epidermal necrolysis caused by her ingestion of the non-steroidal anti-inflammatory drug (NSAID) Toradol, also referred to as ketorolac tromethamine injection.

According to this SJS lawsuit, “[a]lthough decedent was prescribed the branded drug Toradol by her treating physician, she was actually administered Hospira’s reference listed drug (RLD), ketorolac tromethamine injection at Anaheim Medical Center located in Anaheim, California for fever or pain in the emergency room on 3/05/2015.”

The SJS lawsuit goes on to state that Roche, the manufacturer of Toradol, withdrew all of its drugs from the market in August 2004. Following the market withdrawal, the FDA designated ketorolac, manufactured by Hospira, to take the place of Toradol. In 2014, Pfizer joined Hospira in a merger.

According to the claim, Latrisha was a ketorolac injection after complaining of body aches and fever. According to the lawsuit, “She was discharged in good condition without any evidence of a rash, blistering or an allergic reaction whatsoever.”

The following day, Latrisha reported back to the medical center complaining of a rash, difficulty opening her eyes, pain in her eyes and mouth and had painful skin lesions on her face that later spread to her upper extremities and back of her torso.

The emergency room physician concluded that she was having an allergic reaction to Toradol and diagnosed her with possible Stevens Johnson syndrome. She was later transferred to another hospital in a nearby city that offered a higher level of care.

While at the burn unit of the new facility, Latrisha underwent skin biopsy that confirmed she was in fact suffering from toxic epidermal necrolysis (TEN) , a more severe form of Stevens Johnson syndrome. Her condition quickly deteriorated and she developed methicillin-resistant staph aureus (MRSA) pneumonia and sepsis with multi-organ failure.

Despite aggressive treatments with fluids, antibiotics and pressers, Latrisha went into ventricular-tachycardia due to her experience with TEN, and she died. The autopsy confirmed that her cause of death was toxic epidermal necrolysis with secondary sepsis and infections caused by the Toradol injection.

The Toradol Stevens Johnson lawsuit states that the labeling on the Toradol injection did not include the higher risks of SJS and TEN, and did not disclose that females and African-Americans as a whole were more likely to have increased risks of developing the drug reaction, along with poorer outcomes.

As a result of their daughter’s death, the parents raised a number of claims in their Toradol Stevens Johnson lawsuit including wrongful death, survival action, negligence/gross negligence, fraud and negligent misrepresentation, concealment, negligence per se, failure to update/warn, intentional misrepresentation, concealment and manufacturing defects/recalls.

The plaintiffs are seeking compensatory damages, disgorgement of profits, restitution, past and future special damages including loss of consortium funeral, burial and medical expenses, disfigurement, physical impairment, loss of wages, loss of household services, loss of benefits, punitive damages, attorney’s fees and costs and any additional relief as deemed just and proper by the Court.

The Toradol Stevens Johnson Lawsuit is Case No. 5:17-cv-00516-SVW-SP, in the U.S. District Court for the Central District of California.